HUE028656T2 - Biphenyl-4-ylsulfonic acid arylamides and their use as therapeutic agents - Google Patents
Biphenyl-4-ylsulfonic acid arylamides and their use as therapeutic agents Download PDFInfo
- Publication number
- HUE028656T2 HUE028656T2 HUE08718826A HUE08718826A HUE028656T2 HU E028656 T2 HUE028656 T2 HU E028656T2 HU E08718826 A HUE08718826 A HU E08718826A HU E08718826 A HUE08718826 A HU E08718826A HU E028656 T2 HUE028656 T2 HU E028656T2
- Authority
- HU
- Hungary
- Prior art keywords
- independently
- group
- inflammation
- ring
- phenyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 36
- XDTYUYVIGLIFCW-UHFFFAOYSA-N 4-phenylbenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C1=CC=CC=C1 XDTYUYVIGLIFCW-UHFFFAOYSA-N 0.000 title description 2
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 281
- 238000000034 method Methods 0.000 claims description 215
- 238000011282 treatment Methods 0.000 claims description 126
- 230000002265 prevention Effects 0.000 claims description 88
- 125000001424 substituent group Chemical group 0.000 claims description 85
- 206010061218 Inflammation Diseases 0.000 claims description 78
- 230000004054 inflammatory process Effects 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 62
- 230000004913 activation Effects 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 206010065687 Bone loss Diseases 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 210000002997 osteoclast Anatomy 0.000 claims description 42
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 37
- 208000001132 Osteoporosis Diseases 0.000 claims description 34
- 210000000988 bone and bone Anatomy 0.000 claims description 30
- 125000001931 aliphatic group Chemical group 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 206010023203 Joint destruction Diseases 0.000 claims description 28
- 108010002352 Interleukin-1 Proteins 0.000 claims description 27
- 102000000589 Interleukin-1 Human genes 0.000 claims description 27
- 108010025832 RANK Ligand Proteins 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 27
- 201000004681 Psoriasis Diseases 0.000 claims description 24
- 210000000987 immune system Anatomy 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000027866 inflammatory disease Diseases 0.000 claims description 15
- 208000006386 Bone Resorption Diseases 0.000 claims description 14
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 14
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 14
- 230000024279 bone resorption Effects 0.000 claims description 14
- 150000004677 hydrates Chemical class 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 12
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 10
- 239000007943 implant Substances 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000011164 ossification Effects 0.000 claims description 7
- 208000002865 osteopetrosis Diseases 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 230000009826 neoplastic cell growth Effects 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 101150032645 SPE1 gene Proteins 0.000 claims description 3
- 101100233725 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) IXR1 gene Proteins 0.000 claims description 3
- 101150028225 ordA gene Proteins 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 229910017711 NHRa Inorganic materials 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 208000025368 adrenal gland disease Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 132
- 230000015572 biosynthetic process Effects 0.000 description 105
- 238000003786 synthesis reaction Methods 0.000 description 100
- 239000000203 mixture Substances 0.000 description 59
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 49
- -1 class of biphenyl-4-yl-sulfonic acid aryl amides Chemical class 0.000 description 47
- 239000000843 powder Substances 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 108700012920 TNF Proteins 0.000 description 38
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 38
- 239000007787 solid Substances 0.000 description 34
- 239000003921 oil Substances 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000009472 formulation Methods 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 25
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 229940124530 sulfonamide Drugs 0.000 description 23
- 208000020084 Bone disease Diseases 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 125000004093 cyano group Chemical group *C#N 0.000 description 18
- 206010003246 arthritis Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 208000016738 bone Paget disease Diseases 0.000 description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- KTQOCIBRVODXQX-UHFFFAOYSA-N 4-bromo-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 KTQOCIBRVODXQX-UHFFFAOYSA-N 0.000 description 13
- 208000009386 Experimental Arthritis Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 208000010191 Osteitis Deformans Diseases 0.000 description 12
- 208000027067 Paget disease of bone Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 9
- MFHHEDUBMLTGBM-UHFFFAOYSA-N 2-(4-bromophenyl)benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1C1=CC=C(Br)C=C1 MFHHEDUBMLTGBM-UHFFFAOYSA-N 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 208000018937 joint inflammation Diseases 0.000 description 9
- OJZQOQNSUZLSMV-UHFFFAOYSA-N (3-aminophenyl)methanol Chemical compound NC1=CC=CC(CO)=C1 OJZQOQNSUZLSMV-UHFFFAOYSA-N 0.000 description 8
- YGJWYWDUPRPUDG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene;sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O.C1=CC(Br)=CC=C1C1=CC=CC=C1 YGJWYWDUPRPUDG-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 230000028709 inflammatory response Effects 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 7
- 208000037147 Hypercalcaemia Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 239000004305 biphenyl Substances 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000000148 hypercalcaemia Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 229910006074 SO2NH2 Inorganic materials 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 150000003456 sulfonamides Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1Cl QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 5
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 235000010603 pastilles Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002476 tumorcidal effect Effects 0.000 description 5
- IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical compound NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960001251 denosumab Drugs 0.000 description 4
- CLUJXWPKKXFNJY-UHFFFAOYSA-N ethyl 2-[3-[(4-bromophenyl)sulfonylamino]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(NS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 CLUJXWPKKXFNJY-UHFFFAOYSA-N 0.000 description 4
- WQSOFWIIBNJWSS-UHFFFAOYSA-N ethyl 3-amino-4-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(N)=C1 WQSOFWIIBNJWSS-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 231100000747 viability assay Toxicity 0.000 description 4
- 238000003026 viability measurement method Methods 0.000 description 4
- YBNDRTRLXPEWKQ-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1F YBNDRTRLXPEWKQ-UHFFFAOYSA-N 0.000 description 3
- OXSANYRLJHSQEP-UHFFFAOYSA-N 4-aminophthalic acid Chemical compound NC1=CC=C(C(O)=O)C(C(O)=O)=C1 OXSANYRLJHSQEP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102100023118 Transcription factor JunD Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 3
- HYGAZJLADQODNT-UHFFFAOYSA-N ethyl 3-[[4-(2,4-dichlorophenyl)phenyl]sulfonylamino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Cl)=CC=2)Cl)=C1 HYGAZJLADQODNT-UHFFFAOYSA-N 0.000 description 3
- FEJDAOAZBXYWQO-UHFFFAOYSA-N ethyl 3-[[4-(4-bromophenyl)phenyl]sulfonylamino]-4-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 FEJDAOAZBXYWQO-UHFFFAOYSA-N 0.000 description 3
- FYCPYYOESKUODV-UHFFFAOYSA-N ethyl 5-amino-2-hydroxybenzoate Chemical compound CCOC(=O)C1=CC(N)=CC=C1O FYCPYYOESKUODV-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- QQVIHTHCMHWDBS-UHFFFAOYSA-L isophthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC(C([O-])=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-L 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NNHZHTAUBMLREH-UHFFFAOYSA-N (3-amino-2-chlorophenyl)methanol Chemical compound NC1=CC=CC(CO)=C1Cl NNHZHTAUBMLREH-UHFFFAOYSA-N 0.000 description 2
- UVYZMJMDIMWDNJ-UHFFFAOYSA-N (3-amino-2-methylphenyl)methanol Chemical compound CC1=C(N)C=CC=C1CO UVYZMJMDIMWDNJ-UHFFFAOYSA-N 0.000 description 2
- WPUAJRPNIWMHET-UHFFFAOYSA-N (3-amino-4-methoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1N WPUAJRPNIWMHET-UHFFFAOYSA-N 0.000 description 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RENKNADFNRIRNZ-UHFFFAOYSA-N 2-phenylbenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 RENKNADFNRIRNZ-UHFFFAOYSA-N 0.000 description 2
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 2
- GXUHYLLIXHNSEP-UHFFFAOYSA-N 3-[[4-(4-bromophenyl)phenyl]sulfonylamino]-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1O GXUHYLLIXHNSEP-UHFFFAOYSA-N 0.000 description 2
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 2
- IDALEPDEBIYNFL-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Cl)=CC=2)Cl)=C1 IDALEPDEBIYNFL-UHFFFAOYSA-N 0.000 description 2
- TYHUSNQWWKFBCU-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-(4-hydroxybutyl)-3-methylbenzenesulfonamide Chemical compound CC1=CC(S(=O)(=O)NCCCCO)=CC=C1C1=CC=C(F)C=C1F TYHUSNQWWKFBCU-UHFFFAOYSA-N 0.000 description 2
- LVZZTIZRQQRRBM-UHFFFAOYSA-N 4-bromo-n-[4-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 LVZZTIZRQQRRBM-UHFFFAOYSA-N 0.000 description 2
- 208000035939 Alveolitis allergic Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 101100162203 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflG gene Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- QTPBTHFYRUKBEU-UHFFFAOYSA-N diethyl 4-[(4-bromophenyl)sulfonylamino]benzene-1,2-dicarboxylate Chemical compound C1=C(C(=O)OCC)C(C(=O)OCC)=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 QTPBTHFYRUKBEU-UHFFFAOYSA-N 0.000 description 2
- VQRVPAXIXNQFHI-UHFFFAOYSA-N diethyl 5-aminobenzene-1,3-dicarboxylate Chemical compound CCOC(=O)C1=CC(N)=CC(C(=O)OCC)=C1 VQRVPAXIXNQFHI-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- DBKLLINXWSAJQI-UHFFFAOYSA-N ethyl 3-[[4-(2,4-difluorophenyl)phenyl]sulfonylamino]-4-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=C1 DBKLLINXWSAJQI-UHFFFAOYSA-N 0.000 description 2
- WAEJXRZGFVZCFW-UHFFFAOYSA-N ethyl 3-[[4-(2,4-difluorophenyl)phenyl]sulfonylamino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=C1 WAEJXRZGFVZCFW-UHFFFAOYSA-N 0.000 description 2
- UBURNEUETDQIAM-UHFFFAOYSA-N ethyl 5-[[4-(4-bromophenyl)phenyl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OCC)=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 UBURNEUETDQIAM-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003990 molecular pathway Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 230000000010 osteolytic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- XKGOGOLMEYUITI-UHFFFAOYSA-N (3-amino-4-chlorophenyl)methanol Chemical compound NC1=CC(CO)=CC=C1Cl XKGOGOLMEYUITI-UHFFFAOYSA-N 0.000 description 1
- BCQKYGYTOHXGLL-UHFFFAOYSA-N (3-amino-4-methylphenyl)methanol Chemical compound CC1=CC=C(CO)C=C1N BCQKYGYTOHXGLL-UHFFFAOYSA-N 0.000 description 1
- TZHJVLGDHRXGDX-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1Cl TZHJVLGDHRXGDX-UHFFFAOYSA-N 0.000 description 1
- VYEWTHXZHHATTA-UHFFFAOYSA-N (4-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=C(B(O)O)C=C1 VYEWTHXZHHATTA-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- LURSRRLUCSSCHJ-UHFFFAOYSA-N (5-amino-2-chlorophenyl)methanol Chemical compound NC1=CC=C(Cl)C(CO)=C1 LURSRRLUCSSCHJ-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FPNVMCMDWZNTEU-UHFFFAOYSA-N 1-bromo-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1Br FPNVMCMDWZNTEU-UHFFFAOYSA-N 0.000 description 1
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
- PYKQPDVLSIQBIH-UHFFFAOYSA-N 1-nitro-2-phenylbenzene;sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O.[O-][N+](=O)C1=CC=CC=C1C1=CC=CC=C1 PYKQPDVLSIQBIH-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- XUSKZLBLGHBCLD-UHFFFAOYSA-N 2-(3-aminophenyl)acetic acid Chemical compound NC1=CC=CC(CC(O)=O)=C1 XUSKZLBLGHBCLD-UHFFFAOYSA-N 0.000 description 1
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical compound NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 1
- OSPFLFXWBXFPOB-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)benzenesulfonyl chloride Chemical compound FC1=CC(Br)=CC=C1C1=CC=CC=C1S(Cl)(=O)=O OSPFLFXWBXFPOB-UHFFFAOYSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- DHHBRGYFMNXBNU-UHFFFAOYSA-N 2-chloro-n-[3-(hydroxymethyl)phenyl]-4-phenylbenzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C(=CC(=CC=2)C=2C=CC=CC=2)Cl)=C1 DHHBRGYFMNXBNU-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 description 1
- DYAJQJOKLKIBDB-UHFFFAOYSA-N 3-[(4-phenylphenyl)sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 DYAJQJOKLKIBDB-UHFFFAOYSA-N 0.000 description 1
- UEVRZKOMZJXSHK-UHFFFAOYSA-N 3-[[4-(2,4-dichlorophenyl)phenyl]sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Cl)=CC=2)Cl)=C1 UEVRZKOMZJXSHK-UHFFFAOYSA-N 0.000 description 1
- MRBKRZAPGUCWOS-UHFFFAOYSA-N 3-amino-4-hydroxybenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1O MRBKRZAPGUCWOS-UHFFFAOYSA-N 0.000 description 1
- FDGAEAYZQQCBRN-UHFFFAOYSA-N 3-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1N FDGAEAYZQQCBRN-UHFFFAOYSA-N 0.000 description 1
- NMZXRSUKNBTHPJ-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-n-[3-(2-hydroxyethyl)phenyl]benzenesulfonamide Chemical compound OCCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Cl)=CC=2)Cl)=C1 NMZXRSUKNBTHPJ-UHFFFAOYSA-N 0.000 description 1
- IIQBZOLOBUFVDF-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[3-(2-hydroxyethyl)phenyl]benzenesulfonamide Chemical compound OCCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=C1 IIQBZOLOBUFVDF-UHFFFAOYSA-N 0.000 description 1
- XLELBGJNRPBOIX-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[3-(hydroxymethyl)-2-methylphenyl]benzenesulfonamide Chemical compound CC1=C(CO)C=CC=C1NS(=O)(=O)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 XLELBGJNRPBOIX-UHFFFAOYSA-N 0.000 description 1
- YCVYDLLLTPMWEK-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[3-(hydroxymethyl)phenyl]-3-methylbenzenesulfonamide Chemical compound CC1=CC(S(=O)(=O)NC=2C=C(CO)C=CC=2)=CC=C1C1=CC=C(F)C=C1F YCVYDLLLTPMWEK-UHFFFAOYSA-N 0.000 description 1
- WEPXBQIOQPMHDR-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=C1 WEPXBQIOQPMHDR-UHFFFAOYSA-N 0.000 description 1
- ISNSVBPLFWZIHM-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[4-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1NS(=O)(=O)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 ISNSVBPLFWZIHM-UHFFFAOYSA-N 0.000 description 1
- ROXOPCNLHCVRNF-UHFFFAOYSA-N 4-(2-chlorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC=CC=2)Cl)=C1 ROXOPCNLHCVRNF-UHFFFAOYSA-N 0.000 description 1
- XPJUZKAYNJYKSQ-UHFFFAOYSA-N 4-(2-fluorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC=CC=2)F)=C1 XPJUZKAYNJYKSQ-UHFFFAOYSA-N 0.000 description 1
- QSAZPEKRYISSHV-UHFFFAOYSA-N 4-(4-bromo-2-fluorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Br)=CC=2)F)=C1 QSAZPEKRYISSHV-UHFFFAOYSA-N 0.000 description 1
- CDQODTMMLMZFRB-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[2-chloro-3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1Cl CDQODTMMLMZFRB-UHFFFAOYSA-N 0.000 description 1
- RYVRXNQVVJQYRD-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[2-chloro-5-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=C(Cl)C(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 RYVRXNQVVJQYRD-UHFFFAOYSA-N 0.000 description 1
- JDFHTHCSCMMBDG-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[3-(2-hydroxyethyl)phenyl]benzenesulfonamide Chemical compound OCCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 JDFHTHCSCMMBDG-UHFFFAOYSA-N 0.000 description 1
- GRXSAJHUYACZFJ-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[3-(hydroxymethyl)-2-methylphenyl]benzenesulfonamide Chemical compound CC1=C(CO)C=CC=C1NS(=O)(=O)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 GRXSAJHUYACZFJ-UHFFFAOYSA-N 0.000 description 1
- YGXOEYQPJCYRSZ-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 YGXOEYQPJCYRSZ-UHFFFAOYSA-N 0.000 description 1
- KSNQDHQHWUBNRT-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[4-(2-hydroxyethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CCO)=CC=C1NS(=O)(=O)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 KSNQDHQHWUBNRT-UHFFFAOYSA-N 0.000 description 1
- NVTXKFQWGUWMCG-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[4-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CO)=CC=C1NS(=O)(=O)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 NVTXKFQWGUWMCG-UHFFFAOYSA-N 0.000 description 1
- BMVYLRSTLCWYDY-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[4-chloro-3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound C1=C(Cl)C(CO)=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 BMVYLRSTLCWYDY-UHFFFAOYSA-N 0.000 description 1
- JAOSKIKMJDEMGS-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[5-(hydroxymethyl)-2-methoxyphenyl]benzenesulfonamide Chemical compound COC1=CC=C(CO)C=C1NS(=O)(=O)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 JAOSKIKMJDEMGS-UHFFFAOYSA-N 0.000 description 1
- CNMRTADCKHBPKQ-UHFFFAOYSA-N 4-(4-bromophenyl)-n-[5-(hydroxymethyl)-2-methylphenyl]benzenesulfonamide Chemical compound CC1=CC=C(CO)C=C1NS(=O)(=O)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 CNMRTADCKHBPKQ-UHFFFAOYSA-N 0.000 description 1
- XOGMVMSNSCCFPN-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC(Cl)=CC=2)F)=C1 XOGMVMSNSCCFPN-UHFFFAOYSA-N 0.000 description 1
- JNMANBHAWSQRJA-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 JNMANBHAWSQRJA-UHFFFAOYSA-N 0.000 description 1
- BWALKDVQDDXKJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[3-(hydroxymethyl)-2-methylphenyl]benzenesulfonamide Chemical compound CC1=C(CO)C=CC=C1NS(=O)(=O)C1=CC=C(C=2C=CC(F)=CC=2)C=C1 BWALKDVQDDXKJZ-UHFFFAOYSA-N 0.000 description 1
- OUDYKFBFCBMYQR-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[3-(hydroxymethyl)phenyl]-2-(trifluoromethoxy)benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C(=CC(=CC=2)C=2C=CC(F)=CC=2)OC(F)(F)F)=C1 OUDYKFBFCBMYQR-UHFFFAOYSA-N 0.000 description 1
- GDXFBKQIBDULBN-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 GDXFBKQIBDULBN-UHFFFAOYSA-N 0.000 description 1
- XISYTZOJIFWEGV-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(S(=O)(=O)NC=2C=C(CO)C=CC=2)C=C1 XISYTZOJIFWEGV-UHFFFAOYSA-N 0.000 description 1
- ZZCIRIWJHAZTIW-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC(Br)=CC=C1S(Cl)(=O)=O ZZCIRIWJHAZTIW-UHFFFAOYSA-N 0.000 description 1
- LBQQPYOXYVBDLN-UHFFFAOYSA-N 4-bromo-2-chloro-n-[3-(hydroxymethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C(=CC(Br)=CC=2)Cl)=C1 LBQQPYOXYVBDLN-UHFFFAOYSA-N 0.000 description 1
- OECYEHWJPRPCOH-UHFFFAOYSA-N 4-bromo-2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Br)=CC=C1S(Cl)(=O)=O OECYEHWJPRPCOH-UHFFFAOYSA-N 0.000 description 1
- PEKKDCKYNDDVJI-UHFFFAOYSA-N 4-bromo-n-[3-(hydroxymethyl)-2-methylphenyl]benzenesulfonamide Chemical compound CC1=C(CO)C=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 PEKKDCKYNDDVJI-UHFFFAOYSA-N 0.000 description 1
- GOSTYERJRNUOPO-UHFFFAOYSA-N 4-bromo-n-[3-(hydroxymethyl)phenyl]-2-(trifluoromethoxy)benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C(=CC(Br)=CC=2)OC(F)(F)F)=C1 GOSTYERJRNUOPO-UHFFFAOYSA-N 0.000 description 1
- APDFKBPOJIKLSW-UHFFFAOYSA-N 4-bromo-n-[3-(hydroxymethyl)phenyl]-3-methylbenzenesulfonamide Chemical compound C1=C(Br)C(C)=CC(S(=O)(=O)NC=2C=C(CO)C=CC=2)=C1 APDFKBPOJIKLSW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- KBZFDRWPMZESDI-UHFFFAOYSA-N 5-aminobenzene-1,3-dicarboxylic acid Chemical compound NC1=CC(C(O)=O)=CC(C(O)=O)=C1 KBZFDRWPMZESDI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010058284 Allergy to arthropod sting Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 101100322818 Arabidopsis thaliana AHL27 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000251475 Dipnoi Species 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101001108356 Homo sapiens Nardilysin Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- 241000235789 Hyperoartia Species 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000251752 Myxine glutinosa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102100021850 Nardilysin Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000269907 Pleuronectes platessa Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037391 Pulmonary granuloma Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 241000871311 Toxicodendron vernix Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- BDFDXMSSBFNAQG-UHFFFAOYSA-N diethyl 2-aminobenzene-1,4-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(C(=O)OCC)C(N)=C1 BDFDXMSSBFNAQG-UHFFFAOYSA-N 0.000 description 1
- PJARQNJKDUFHOZ-UHFFFAOYSA-N diethyl 3-aminobenzene-1,2-dicarboxylate Chemical compound CCOC(=O)C1=CC=CC(N)=C1C(=O)OCC PJARQNJKDUFHOZ-UHFFFAOYSA-N 0.000 description 1
- DNMCODGUPCSEOC-UHFFFAOYSA-N diethyl 4-[[4-(2,4-dichlorophenyl)phenyl]sulfonylamino]benzene-1,2-dicarboxylate Chemical compound C1=C(C(=O)OCC)C(C(=O)OCC)=CC=C1NS(=O)(=O)C1=CC=C(C=2C(=CC(Cl)=CC=2)Cl)C=C1 DNMCODGUPCSEOC-UHFFFAOYSA-N 0.000 description 1
- MPCAOTRSCWFYIJ-UHFFFAOYSA-N diethyl 4-aminobenzene-1,2-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(N)C=C1C(=O)OCC MPCAOTRSCWFYIJ-UHFFFAOYSA-N 0.000 description 1
- JWELZQZRNUOFHS-UHFFFAOYSA-N diethyl 4-aminobenzene-1,3-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(N)C(C(=O)OCC)=C1 JWELZQZRNUOFHS-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NTBHQNDXAJXRPU-UHFFFAOYSA-N dimethyl 4-aminobenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=C(N)C=C1C(=O)OC NTBHQNDXAJXRPU-UHFFFAOYSA-N 0.000 description 1
- JHGWAPONRAIFDC-UHFFFAOYSA-N dimethyl 5-[(4-bromophenyl)sulfonylamino]benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(C(=O)OC)=CC(NS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 JHGWAPONRAIFDC-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- BUQDFYLTBZBICF-UHFFFAOYSA-N ethyl 2-[3-[[2-(4-bromophenyl)phenyl]sulfonylamino]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC(Br)=CC=2)=C1 BUQDFYLTBZBICF-UHFFFAOYSA-N 0.000 description 1
- DCFLSWOGMMLEQN-UHFFFAOYSA-N ethyl 3-[[4-(4-bromophenyl)phenyl]sulfonylamino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 DCFLSWOGMMLEQN-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000009113 gold standard therapy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000011384 malt worker lung Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- LKBHTTUMNUXOJQ-UHFFFAOYSA-N n-[3-(hydroxymethyl)phenyl]-4-(2-nitrophenyl)benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C(=CC=CC=2)[N+]([O-])=O)=C1 LKBHTTUMNUXOJQ-UHFFFAOYSA-N 0.000 description 1
- SMYLZNHIXOJDLE-UHFFFAOYSA-N n-[3-(hydroxymethyl)phenyl]-4-(4-methylphenyl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=CC=C(S(=O)(=O)NC=2C=C(CO)C=CC=2)C=C1 SMYLZNHIXOJDLE-UHFFFAOYSA-N 0.000 description 1
- OEYKZUYKVLHVEY-UHFFFAOYSA-N n-[3-(hydroxymethyl)phenyl]-4-(4-methylsulfonylphenyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=C(S(=O)(=O)NC=2C=C(CO)C=CC=2)C=C1 OEYKZUYKVLHVEY-UHFFFAOYSA-N 0.000 description 1
- HAKKERBWPNWSAP-UHFFFAOYSA-N n-[3-(hydroxymethyl)phenyl]-4-[4-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 HAKKERBWPNWSAP-UHFFFAOYSA-N 0.000 description 1
- QISRVSILAPJTBL-UHFFFAOYSA-N n-[3-(hydroxymethyl)phenyl]-4-phenylbenzenesulfonamide Chemical compound OCC1=CC=CC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 QISRVSILAPJTBL-UHFFFAOYSA-N 0.000 description 1
- UIWUPWODEIEEJS-UHFFFAOYSA-N n-[4-[4-[[3-(hydroxymethyl)phenyl]sulfamoyl]phenyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(S(=O)(=O)NC=2C=C(CO)C=CC=2)C=C1 UIWUPWODEIEEJS-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000020404 regulation of osteoclast differentiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000030432 tumor necrosis factor (ligand) superfamily member 11 production Effects 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000000834 ventilation pneumonitis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0705400.0A GB0705400D0 (en) | 2007-03-21 | 2007-03-21 | Therapeutic compounds andm their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028656T2 true HUE028656T2 (en) | 2016-12-28 |
Family
ID=38024559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08718826A HUE028656T2 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-ylsulfonic acid arylamides and their use as therapeutic agents |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524778B2 (OSRAM) |
| EP (1) | EP2137141B1 (OSRAM) |
| JP (1) | JP5450105B2 (OSRAM) |
| CA (1) | CA2681320C (OSRAM) |
| DK (1) | DK2137141T3 (OSRAM) |
| ES (1) | ES2561163T3 (OSRAM) |
| GB (1) | GB0705400D0 (OSRAM) |
| HR (1) | HRP20160183T1 (OSRAM) |
| HU (1) | HUE028656T2 (OSRAM) |
| SI (1) | SI2137141T1 (OSRAM) |
| WO (1) | WO2008114022A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| US9233946B2 (en) | 2010-09-17 | 2016-01-12 | Kancera Ab | Sulfonamide compounds |
| US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
| WO2012173987A2 (en) | 2011-06-13 | 2012-12-20 | Ergon Pharmaceuticals Llc | Methods of treatment using a bcat1 inhibitor |
| US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| EP2794009B1 (en) * | 2011-12-22 | 2017-08-30 | Kancera AB | Bisarylsulfonamides useful in the treatment of inflammation and cancer |
| MX2015006844A (es) * | 2012-12-10 | 2015-09-16 | Hoffmann La Roche | Derivados de bencilsulfonamida como moduladores del receptor huerfano relacionado al receptor de retinoide (rorc). |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3046561B1 (en) | 2013-09-20 | 2023-02-22 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| WO2018146129A1 (en) | 2017-02-07 | 2018-08-16 | Orthogenics As | Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening |
| WO2020097408A1 (en) * | 2018-11-09 | 2020-05-14 | Nimbus Artemis, Inc. | Acly inhibitors and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| US4119784A (en) * | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| AU1118097A (en) | 1995-10-30 | 1997-05-22 | Smithkline Beecham Corporation | Protease inhibitors |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| PL331338A1 (en) | 1996-07-22 | 1999-07-05 | Monsanto Co | Thiosulphonamidic metaloprotease inhibitors |
| AU731737B2 (en) | 1996-10-16 | 2001-04-05 | Wyeth Holdings Corporation | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| AU6780398A (en) | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| HUP0002951A3 (en) | 1997-05-08 | 2002-10-28 | Smithkline Beecham Corp | Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DE59802394D1 (de) | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| AP1269A (en) | 1998-01-23 | 2004-04-03 | Aventis Pharma Deutschland Gmbh | Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| WO2001070720A2 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| NZ541950A (en) | 2001-08-09 | 2007-02-23 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) * | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| AU2003221160A1 (en) | 2002-03-27 | 2003-10-08 | Shionogi And Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| ATE469903T1 (de) | 2002-09-04 | 2010-06-15 | Schering Corp | Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine |
| DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| DK1638544T3 (da) | 2003-05-07 | 2008-03-31 | Univ Aberdeen | Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1696915A1 (en) | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| GB0405193D0 (en) * | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| EP1756025A1 (en) | 2004-05-05 | 2007-02-28 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) * | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| KR20080016649A (ko) | 2005-06-16 | 2008-02-21 | 화이자 인코포레이티드 | Ｎ-(피리딘-2-일)-술폰아미드 유도체 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) * | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| EP1984344B1 (en) | 2005-12-29 | 2012-09-26 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2007
- 2007-03-21 GB GBGB0705400.0A patent/GB0705400D0/en not_active Ceased
-
2008
- 2008-03-20 WO PCT/GB2008/000989 patent/WO2008114022A1/en not_active Ceased
- 2008-03-20 HU HUE08718826A patent/HUE028656T2/en unknown
- 2008-03-20 DK DK08718826.4T patent/DK2137141T3/en active
- 2008-03-20 US US12/531,732 patent/US8524778B2/en active Active
- 2008-03-20 JP JP2009554083A patent/JP5450105B2/ja active Active
- 2008-03-20 CA CA2681320A patent/CA2681320C/en active Active
- 2008-03-20 EP EP08718826.4A patent/EP2137141B1/en active Active
- 2008-03-20 HR HRP20160183T patent/HRP20160183T1/hr unknown
- 2008-03-20 SI SI200831582T patent/SI2137141T1/sl unknown
- 2008-03-20 ES ES08718826.4T patent/ES2561163T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010522152A (ja) | 2010-07-01 |
| JP5450105B2 (ja) | 2014-03-26 |
| SI2137141T1 (sl) | 2016-03-31 |
| EP2137141A1 (en) | 2009-12-30 |
| CA2681320C (en) | 2015-05-19 |
| WO2008114022A1 (en) | 2008-09-25 |
| GB0705400D0 (en) | 2007-05-02 |
| ES2561163T3 (es) | 2016-02-24 |
| CA2681320A1 (en) | 2008-09-25 |
| US8524778B2 (en) | 2013-09-03 |
| EP2137141B1 (en) | 2015-12-02 |
| HRP20160183T1 (hr) | 2016-03-25 |
| US20100286266A1 (en) | 2010-11-11 |
| DK2137141T3 (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2137141T3 (en) | Biphenyl-4-YL-SULFONSYREARYLAMIDER and their use as therapeutic agents | |
| ES2544511T3 (es) | Compuestos de aril-fenil-sulfonamido-cicloalquilo y su uso | |
| EP2349990B1 (en) | Aryl-phenyl-sulfonamide-phenylene compounds and their use | |
| KR100247672B1 (ko) | N-(4-아릴-티아졸-2-일)-설폰아미드 유도체를 함유하는 약제학적 조성물 | |
| US20180037544A1 (en) | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use | |
| US7560597B2 (en) | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |